



Quality Council
May 15, 2025

Call to Order and Roll Call

Agenda

<u>Time</u>	<u>Topic</u>
3:00 p.m.	Call to Order, Roll Call, and Agenda Review
3:05 p.m.	Approval of April 17, 2025 Meeting Minutes — Vote
3:10 p.m.	Continue Process of Setting 2026–2030 Quality Benchmarks
4:50 p.m.	Public Comment
4:55 p.m.	Next Steps and Adjournment

Approval of April 17, 2025 Meeting Minutes – Vote

Continue Process of Setting 2026 – 2030 Quality Benchmarks

Reminder: Statutory Requirements

- Connecticut General Statute (C.G.S.) § 19a-754g states that “**not later than July 1, 2025**, and every five years thereafter, the executive director shall **develop and adopt annual health care quality benchmarks for the succeeding five calendar years** for provider entities and payers.”
- C.G.S § 19a-754g goes on to say that “the executive director shall consider (i) quality measures endorsed by nationally recognized organizations... and (ii) measures that:
 - (I) concern health outcomes, overutilization, underutilization and patient safety,
 - (II) meet standards of patient-centeredness and ensure consideration of differences in preferences and clinical characteristics within patient subpopulations, and
 - (III) concern community health or population health.”

Reminder: The Quality Benchmarks Logic Model



Setting 2026–2030 Quality Benchmarks: Process Overview

1. Review the **charge** outlined in statute and an **overview of the process** the Council will undertake.
2. Discuss the Quality Benchmarks **logic model**.
3. Review **experience with and performance on** the Quality Benchmarks to date.
4. Revisit the 2021 Quality Council **criteria for selecting measures** and adopt criteria for this year's process.
5. Determine the **number of Quality Benchmarks to set** and whether to again include measures of both **healthcare** and **health status**.
6. Consider **candidate measures**.
7. Determine whether to use a **phased approach** to implementation.
8. Review **recent performance and relevant benchmarks** for selected measures to inform **development of Quality Benchmark values**.

March and April Meeting Recap

- During our March meeting, members recommended setting **six** Quality Benchmarks for 2026–2030.
 - Members recommended that the Quality Benchmarks be entirely comprised of **healthcare measures**.
- During the March and April meetings, the Council narrowed the pool of potential 2026–2030 Quality Benchmark measures down to eight “finalists”, which are displayed on the following slides.

Final Eight Candidate Quality Benchmarks (1 of 2)

Measure Name	Steward	Data Source	2026 Measure Set Status	2025 Payer Use	2023 Performance	
					Comm.	Medicaid
Child and Adolescent Well-Care Visits	NCQA	Claims	Core	6	81.2	66.9
Controlling High Blood Pressure	NCQA	EHR	Core	5	71.1	70.4
Glycemic Status Assessment	NCQA	EHR	Core	4	22.0	29.3
Prenatal & Postpartum Care	NCQA	Claims	Core	3	Pre: 86.2	Pre: 93.7
					Post: 89.5	Post: 88.7

Final Eight Candidate Quality Benchmarks (2 of 2)

Measure Name	Steward	Data Source	2026 Measure Set Status	2025 Payer Use	2023 Performance	
					Comm.	Medicaid
Childhood Immunization Status	NCQA	Claims	Menu	4*	70.2	53.0
Immunizations for Adolescents	NCQA	Claims	Menu	3	25.9	37.9
Breast Cancer Screening	NCQA	Claims	Menu	6	83.9	57.5
Colorectal Cancer Screening	NCQA	EHR	Menu	4	77.7	30.2

Recommending Six 2026–2030 Quality Benchmarks

- In between meetings, OHS distributed a summary of the remaining eight candidate measures along with a survey asking members to rank the measures.
- Survey results TBD

Recommending Quality Benchmark Target Values (1 of 2)

- For the six measures, we will now review performance data by market relative to available benchmarks from NCQA's Quality Compass to inform the recommendation of target values.
 - For each market, we will review performance relative to national benchmarks (25th, 50th, 75th, and/or 90th).
 - For measures with performance near or above the 90th percentile nationally, we will consider relevant New England benchmarks, as New England insurers typically outperforms the national average.
- Today, we will discuss benchmark values for the **commercial** and **Medicaid** markets.
 - ***Does the Quality Council recommend that OHS continue setting Quality Benchmarks for Medicare Advantage?***
 - If so, we will discuss benchmark values for Medicare Advantage during the June meeting.

Recommending Quality Benchmark Target Values (2 of 2)

- Discussion of target values should focus on what members believe performance should be, and realistically can be, at the end of the five-year period (i.e., 2030), with consideration of current performance.
- OHS will then calculate the Compound Annual Growth Rate (CAGR) for each measure based on the baseline rate and target value for 2030 to compute what gradual interim targets would be for 2026–2029.

$$\text{Compound Annual Growth Rate (CAGR)} = \frac{\text{Final Rate}}{\text{Baseline Rate}}^{\frac{1}{\# \text{ years}}} - 1$$

Breast Cancer Screening: Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 (the most recent year for which data are available) was **83.9%, above the national 90th percentile benchmark.**
- Relevant 2023 commercial benchmarks of note include:
 - New England 90th: **85.0%**
 - New England 95th: **85.3%**

What do members believe the commercial target value for *Breast Cancer Screening* should be in 2030?

Breast Cancer Screening: Medicaid

- Medicaid performance for this measure in 2023 was **57.5%, between the national 50th and 75th percentile benchmarks.**
- Relevant 2023 Medicaid benchmarks of note include:
 - National 75th: **59.5%**
 - National 90th: **63.5%**

What do members believe the Medicaid target value for *Breast Cancer Screening* should be in 2030?

Child and Adolescent Well-Care Visits: Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **81.2%, above the national 90th percentile benchmark.**
- Relevant 2023 commercial benchmarks of note include:
 - New England 90th: **82.3%**
 - New England 95th: **83.4%**

What do members believe the commercial target value for *Child and Adolescent Well-Care Visits* should be in 2030?

Child and Adolescent Well-Care Visits: Medicaid

- DSS performance for this measure in 2023 was **66.9%, above the national 90th percentile benchmark.**
- Relevant 2023 Medicaid benchmarks of note include:
 - New England 95th: **73.4%**

What do members believe the Medicaid target value for *Child and Adolescent Well-Care Visits* should be in 2030?

Childhood Immunization Status (Combo 10): Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **70.2%, above the national 90th percentile benchmark.**
- Relevant 2023 commercial benchmarks of note include:
 - New England 90th: **73.5%**
 - New England 95th: **77.2%**

What do members believe the commercial target value for *Childhood Immunization Status* should be in 2030?

Childhood Immunization Status (Combo 10): Medicaid

- DSS performance for this measure in 2023 was **53.0%, above the national 90th percentile benchmark.**
- 2023 DSS performance **also exceeds the New England 95th percentile of 52.8%.**

What do members believe the Medicaid target value for *Childhood Immunization Status* should be in 2030?

Colorectal Cancer Screening: Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **77.7%, above the national 90th percentile benchmark.**
- Connecticut 2023 commercial performance **also exceeds the New England 95th percentile of 77.5%.**

What do members believe the commercial target value for *Colorectal Cancer Screening* should be in 2030?

Colorectal Cancer Screening: Medicaid

- DSS performance for this measure in 2023 was **30.2%, below the national 25th percentile benchmark.**
- Relevant 2023 Medicaid benchmarks of note include:
 - National 25th: **31.6%**
 - National 50th: **38.1%**

What do members believe the Medicaid target value for *Colorectal Cancer Screening* should be in 2030?

Controlling High Blood Pressure: Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **71.1%, between the national 75th and 90th percentile benchmarks.**
- The 2023 national 90th percentile commercial benchmark is **75.8%.**

What do members believe the commercial target value for *Controlling High Blood Pressure* should be in 2030?

Controlling High Blood Pressure: Medicaid

- DSS performance for this measure in 2023 was **70.4**, **between the national 75th and 90th percentile benchmarks.**
- Relevant 2023 Medicaid benchmarks of note include:
 - National 90th: **72.8%**
 - New England 75th: **73.2%**
 - New England 90th and 95th: **75.4%**

What do members believe the Medicaid target value for *Controlling High Blood Pressure* should be in 2030?

Glycemic Status > 9.0%: Commercial

- Note: lower rates reflect better performance for this measure.
- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **22.0%, between the national 75th and 90th percentile benchmarks.**
- The 2023 national 90th percentile commercial benchmark is **18.5%.**

What do members believe the commercial target value for *Glycemic Status > 9.0%* should be in 2030?

Glycemic Status > 9.0%: Medicaid

- Note: lower rates reflect better performance for this measure.
- DSS performance for this measure in 2023 was **29.3%, between the national 75th and 90th percentile benchmarks.**
- Relevant 2023 Medicaid benchmarks of note include:
 - National 90th: **27.0%**
 - New England 75th: **25.8%**
 - New England 90th: **22.4%**

What do members believe the Medicaid target value for *Glycemic Status > 9.0%* should be in 2030?

Immunizations for Adolescents (Combo 2): Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for this measure in 2023 was **25.9%, between the national 25th and 50th percentile benchmarks.**
- Relevant 2023 commercial benchmarks of note include:
 - National 50th: **31.2%**
 - National 75th: **38.4%**

What do members believe the commercial target value for *Immunizations for Adolescents* should be in 2030?

Immunizations for Adolescents (Combo 2): Medicaid

- DSS performance for this measure in 2023 was **37.9%, between the national 50th and 75th percentile benchmarks.**
- Relevant 2023 Medicaid benchmarks of note include:
 - National 75th: **41.6%**
 - National 90th: **48.7%**

What do members believe the Medicaid target value for *Immunizations for Adolescents* should be in 2030?

Timeliness of Prenatal Care: Commercial

- *Prenatal and Postpartum Care* consists of two rates: *Timeliness of Prenatal Care* and *Postpartum Care*.
- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for *Timeliness of Prenatal Care* in 2023 was **86.2%, between the national 50th and 75th percentile benchmarks.**
- Relevant 2023 commercial benchmarks of note include:
 - National 75th: **89.6%**
 - National 90th: **93.9%**

What do members believe the commercial target value for *Timeliness of Prenatal Care* should be in 2030?

Timeliness of Prenatal Care: Medicaid

- DSS performance for *Timeliness of Prenatal Care* in 2023 was **93.7%, above the national 90th percentile benchmark.**
- Relevant 2023 Medicaid benchmarks of note include:
 - New England 90th: **94.6%**
 - New England 95th: **96.4%**

What do members believe the Medicaid target value for *Timeliness of Prenatal Care* should be in 2030?

Postpartum Care: Commercial

- Based on a weighted average of the largest plans in the state, Connecticut commercial performance for *Postpartum Care* in 2023 was **89.5%, between the national 50th and 75th percentile benchmarks.**
- Relevant 2023 commercial benchmarks of note include:
 - National 75th: **90.0%**
 - National 90th: **93.9%**

What do members believe the commercial target value for *Postpartum Care* should be in 2030?

Postpartum Care: Medicaid

- DSS performance for *Postpartum Care* in 2023 was **88.7%, above the national 90th percentile benchmark.**
- Relevant 2023 Medicaid benchmarks of note include:
 - New England 95th: **90.0%**

What do members believe the Medicaid target value for *Postpartum Care* should be in 2030?

Public Comment

Wrap-Up and Next Steps

Meeting Wrap-Up and Next Steps

- The Quality Council will meet next on **Thursday, June 5th from 3–5 pm.**